SillaJen IPO Part 3 - Competitive Strengths of Product (Pexa-Vec)
*Â In Part 3 (as below), I summarized the competitive strengths of product (Pexa-Vec).SillaJen's Pexa-Vec is an advanced liver cancer treatment...
390 Views
Recap of Samsung BioLogics' First Trading Day - Foreign Institutions Net Purchased 1M Shares
Samsung BioLogics closed at ₩144,000 with 6.67% gain on its first trading day. It started with a relatively weak sentiment at the opening price of...
388 Views
Samsung BioLogics' First Trading Day - Blunders in Barron's Argument & Price Prediction
As reported by Barron's on Nov 5 ("Samsung BioLogics IPO: Too Expensive"), there are still some skeptical views on BioLogics' IPO valuation....
455 Views
One World, Two Stories
Celltrion's management continues to make very optimistic projections about Remsima's US sales in 2017 despite regulatory hurdles that will limit...
338 Views
SillaJen IPO Part 2 - Growth Potential & Appropriate Valuation Level
* In Part 2 (as below), I summarized the growth potential and appropriate valuation level of SillaJen.Apparently, not many people are doubtful...
406 Views